Muscular Therapies Headquarters

Looking for information about Muscular Therapies Headquarters? The links below have collected all the necessary data.

Home - Meilus

https://meilus.com/

Since coming to Meilus Muscular Therapy and Sports what I am seeing as a result is the treatment here is moving me to where stretching can become more effective. I thought I was strong but I’m finding out I’m just really tight. ... Meilus Corporate Headquarters …

About Us Muscle Activation Techniques®

http://muscleactivation.com/about-us/

See for yourself what MAT® can do for you to decrease muscular imbalances and address muscle pain. Call 303-745-4270 Ext. 1 to schedule your appointment today at our Denver World Headquarters office, or visit our Find a Specialist page to find a practitioner near you! FIND A …

Muscle Activation Techniques® Restore Movement ...

http://muscleactivation.com/

Muscle Activation Techniques (MAT)® is a powerful muscular assessment tool that analyzes and corrects muscular imbalances. At MAT we focus on the cause of the imblance by testing, correcting, and maintaining muscle contractile efficiency. We believe that flexibility is a derivative of strength, and that muscle tightness is secondary to muscle ...

Merz lands FDA approval for new use of muscle treatment ...

https://www.wraltechwire.com/2020/08/21/merz-lands-fda-approval-for-new-use-of-muscle-treatment-its-n-american-hq-is-in-raleigh/

Aug 21, 2020 · RESEARCH TRIANGLE PARK – Merz Therapeutics, with North American headquarters in Raleigh, has gained a new use for Xeomin, its botulinum toxin therapy…Estimated Reading Time: 5 mins

Muscular Dystrophy Support Centre LinkedIn

https://www.linkedin.com/company/muscular-dystrophy-support-centre

Muscular Dystrophy Support Centre 21 followers on LinkedIn. We’re on a mission to transform access to specialised therapies for people living w. muscular dystrophy in the Midlands There are ...

Pipeline - Dystrogen Therapeutics Corporation

http://dystrogen.com/pipeline/

cell-based therapies Duchenne Muscular Dystrophy Dystrophin Expressing Chimeric Cells (DEC) based therapy developed by Dystrogen Therapeutics aims to target all patients suffering from Duchenne muscular dystrophy, irrespective of existing genetic mutation.